Frøya, 19 June 2025: Reference is made to the stock exchange announcement made by Kaldvík AS ("Kaldvík" or the "Company") on 5 June 2025 (the "Announcement"), regarding the successful completion of a private placement (the "Private Placement") of new shares in the Company raising gross proceeds of approximately NOK 532 million, equal to approximately EUR 46.2 million. As described in the Announcement, the Private Placement consists of two tranches, of which tranche 1 comprises 5,976,172 offer shares ("Tranc ...

Amid so much macro uncertainty, global companies signal optimism to Wall Street. According to data from Wall Street Horizon through June 16, 2025, there’s a net 21 percentage-point positive differential between dividend raisers and slashers—the best Q2 going back several years.Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a co ...

Core Insights - Pfizer is a leading player in oncology with a strong portfolio of approved cancer medicines and a robust pipeline focusing on various modalities, including small molecules and antibody-drug conjugates [1] - The acquisition of Seagen in 2023 enhanced Pfizer's oncology position by adding four ADCs, contributing significantly to revenues in 2024 and Q1 2025, with oncology revenues growing 7% operationally in Q1 2025 [2][8] - Pfizer is expanding its oncology pipeline with several late-stage candidates and has entered the biosimilars market, marketing six cancer biosimilars [3][4] Company Developments - The Seagen acquisition added four ADCs: Adcetris, Padcev, Tukysa, and Tivdak, which have positively impacted Pfizer's revenue [2] - Pfizer has advanced its oncology clinical pipeline with candidates like sasanlimab, vepdegestrant, and sigvotatug vedotin, and has secured an exclusive licensing deal with 3SBio for a dual PD-1 and VEGF inhibitor [3] - The company is also working on expanding the labels of existing oncology products, indicating a proactive approach to enhance its market offerings [4] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Bristol-Myers, with AstraZeneca's oncology sales comprising about 41% of total revenues and growing 13% in Q1 2025 [5] - Merck's Keytruda accounts for approximately 50% of its pharmaceutical sales, while Bristol-Myers' Opdivo represents around 20% of its total revenues [6] Financial Performance - Pfizer's stock has declined 6.8% year-to-date, contrasting with a 0.2% increase in the industry [7] - The company's oncology revenues rose 7% in Q1 2025, driven by key drugs such as Xtandi, Lorbrena, and Padcev [8] - Pfizer's 2025 EPS estimate has increased to $3.06, with a forward P/E ratio of 7.77, which is below the industry average of 15.05 [10][12] Valuation Insights - From a valuation perspective, Pfizer appears attractive, trading below its 5-year mean P/E of 10.90 [10] - The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 to $3.06 per share over the past 60 days, indicating positive sentiment [12]

Key Takeaways Synchrony partners with Payzer to integrate financing into a digital platform for home contractors. Contractors can now offer financing, manage pre-qualifications and get instant credit decisions via Payzer. SYF expands in-home services as BNPL demand rises, while Payzer adds value for mid-sized contractors.A leading consumer financing player, Synchrony Financial (SYF) , recently collaborated with Payzer to develop an integrated digital solution for residential contractors. The initiative is ...

Over the past six months, Annaly Capital Management (NLY) shares have gained 8% compared with the industry’s rise of 1.7%.Price Performance Image Source: Zacks Investment Research NLY has also outperformed its peers AGNC Investment (AGNC) and Arbor Realty Trust (ABR) over the same time frame. AGNC Investment has grown 5.7%, while Arbor Realty has fallen 20.9%.Annaly is a mortgage real estate investment trust that primarily owns, manages and finances a portfolio of real estate-related investment securities. ...

Key Takeaways FSLR stock has dropped 21.2% in six months, underperforming peers and broader energy and market indices. Earnings fell 11.4% in Q1, with warranty charges and tariffs weighing on 2025 guidance and near-term outlook. FSLR is expanding U.S. manufacturing and projects 16% revenue growth in both 2025 and 2026.Shares of First Solar Inc. (FSLR) have plunged 21.2% in the past six months, underperforming the Zacks solar industry’s decline of 19.3% as well as the broader Zacks Oil-Energy sector’s grow ...

Key Takeaways WMT's omnichannel model, ad revenues and memberships drive steady growth and margin expansion. TJX posted 3% comp sales growth and expanded its store base to 5,121 with strong global performance. WMT shares have surged 39.8% over 12 months, outpacing TJX's 11% rise and the broader market.As consumers prioritize value in today’s cost-conscious retail environment, two retail leaders — Walmart Inc. (WMT) and The TJX Companies, Inc. (TJX) — have emerged as top contenders for investor attention. ...

Core Viewpoint - Intuitive Surgical has demonstrated impressive stock performance in the healthcare sector, driven by innovative robotics-assisted surgical devices that have garnered significant demand from medical professionals globally [1]. Company Performance - As of June 17, Intuitive Surgical's stock price is $509.49, with a P/E ratio of 74.71 and a price target of $588.95, indicating a potential upside of 15.60% [2][8]. - The stock has achieved a return of nearly 167% over the past three years, significantly outperforming the S&P 500 Index, which returned approximately 70% during the same period [2]. Analyst Opinions - Analysts are divided on the stock's valuation; Deutsche Bank's price target of $440 suggests a 14% downside, while Citigroup's target of $650 indicates a 27% upside [3]. - The consensus rating for Intuitive Surgical is a Moderate Buy, based on 20 analyst ratings [8][12]. Market Challenges - Tariffs are expected to negatively impact gross margins by 1.7% in 2025, with the company unable to mitigate these effects in the short term [3][4]. - Increased competition is emerging, particularly from Medtronic's Hugo system, which has already received regulatory clearance and shows a high surgical success rate [5][6]. Growth Potential - Approximately 58% of Intuitive's 10,189 Da Vinci systems are located in the U.S., indicating significant growth opportunities in international markets [4]. - The company believes it is "less than one-third penetrated" in its current markets, suggesting ample room for expansion as robotic-assisted surgeries are not yet widely adopted [8][9]. Competitive Advantages - Intuitive Surgical benefits from a two-decade head start over competitors, providing a scale advantage and established trust with healthcare providers [7]. - Despite the high forward P/E multiple of around 63x, this is justified given the company's dominant market position and growth potential [10].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market within a 30-day timeframe [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios, while Growth Score assesses a company's financial health and future growth potential [3][4] - Momentum Score focuses on stocks with upward or downward price trends, helping investors time their purchases effectively [5] - VGM Score combines the three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - To optimize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] Stock Highlight: Lyft (LYFT) - Lyft, founded in 2012 and publicly traded since March 2019, currently holds a Zacks Rank of 2 (Buy) and a VGM Score of A [11] - The company has a Value Style Score of B, supported by a forward P/E ratio of 13.27, indicating attractive valuation metrics [12] - Recent upward revisions in earnings estimates by analysts and a Zacks Consensus Estimate increase to $1.11 per share further enhance Lyft's investment appeal [12]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's future growth potential based on earnings and sales [4] - Momentum Score evaluates stocks based on recent price trends and earnings estimate changes [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically outperformed the S&P 500, achieving an average annual return of +25.41% since 1988 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Company Spotlight: Federated Hermes - Federated Hermes, Inc. is a global asset manager with $839.8 billion in assets under management as of March 31, 2025 [11] - The company currently holds a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating solid performance metrics [11] - Recent analyst revisions have increased the earnings estimate for fiscal 2025 by $0.42 to $4.33 per share, with an average earnings surprise of 13.1% [12]